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procalciﬁc effects of statins in vitro, it remains unclear if statins can modulate coronary atheroma calciﬁcation in vivo.
OBJECTIVES This study compared changes in coronary atheroma volume and calcium indices (CaI) in patients receiving
high-intensity statin therapy (HIST), low-intensity statin therapy (LIST), and no-statin therapy.
METHODS In a post-hoc patient-level analysis of 8 prospective randomized trials using serial coronary intravascular
ultrasound, serial changes in coronary percent atheroma volume (PAV) and CaI were measured across matched coronary
segments in patients with coronary artery disease.
RESULTS Following propensity-weighted adjustment for differences in baseline and changes in clinical, laboratory, and
ultrasonic characteristics, HIST (n ¼ 1,545) associated with PAV regression from baseline (0.6  0.1%; p < 0.001),
whereas both LIST (n ¼ 1,726) and no-statin therapy (n ¼ 224) associated with PAV progression (þ0.8  0.1% and þ1.0
 0.1%; p < 0.001, respectively; p < 0.001 for both HIST vs. LIST and HIST vs. no-statin; p ¼ 0.35 for LIST vs. no-statin).
Signiﬁcant increases in CaI from baseline were noted across all groups (median [interquartile range] HIST, þ0.044
[0.0–0.12]; LIST, þ0.038 [0.0–0.11]; no-statin, þ0.020 [0.0–0.10]; p < 0.001 for all), which could relate to statin
intensity (p ¼ 0.03 for LIST vs. no-statin; p ¼ 0.007 for HIST vs. no-statin; p ¼ 0.18 for HIST vs. LIST). No correlations
were found between changes in CaI and on-treatment levels of atherogenic and antiatherogenic lipoproteins, and
C-reactive protein, in either of the HIST groups or the no-statin group.
CONCLUSIONS Independent of their plaque-regressive effects, statins promote coronary atheroma calciﬁcation. These
ﬁndings provide insight as to how statins may stabilize plaque beyond their effects on plaque regression. (J Am Coll
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ABBR EV I A T I ON S
AND ACRONYMS
CaI = calcium index
CRP = C-reactive protein
CT = computed tomography
HIST = high-intensity
statin therapy
IVUS = intravascular
ultrasound
LDL-C = low-density
lipoprotein cholesterol
LIST = low-intensity
statin therapy
PAV = percent
atheroma volume
TAV = total atheroma volu
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1274S tatins are the cornerstone for treatingatherosclerotic cardiovascular diseaseand can regress atherosclerosis (1,2)
and lower cardiovascular event rates (3).
The most recent U.S. guidelines now advo-
cate high-intensity statin therapy (HIST) in
all individuals with known atherosclerosis,
regardless of baseline lipoprotein levels (4).SEE PAGE 1283Coronary arterial calciﬁcation has been
extensively evaluated, and the baseline
extent of coronary calcium measured nonin-
vasively strongly associates with incident
cardiovascular events (5). Underlying this
imaging approach is the presumption thatcoronary calcium scoring using computed tomogra-
phy (CT) represents a reliable surrogate measure of
coronary atheroma volume. Given the direct relation-
ship between achieved low-density lipoprotein
cholesterol (LDL-C) levels, serial measures of plaque
burden, and cardiovascular events, it is therefore
logical to deduce that the effects on both plaque
and its calciﬁc component following statin therapy
might be concordant. However, prior serial CT evalu-
ations of the effect of statins on coronary calciﬁcation
yielded conﬂicting results (6–11).
Mechanistic studies have demonstrated the po-
tential procalciﬁc effects of statins in vitro (12). Cor-
onary intravascular ultrasound (IVUS) has high
imaging resolution for measuring atheroma volume,
and techniques to measure plaque calciﬁcation on
IVUS are well described (13). Moreover, serial coro-
nary IVUS has been pivotal in elucidating factors
promoting the progression and regression of coronary
atheroma (14). Using serial coronary IVUS in patients
with coronary artery disease, we tested the hypoth-
esis that statin therapy would associate with concor-
dant changes of both coronary atheroma volume and
plaque calciﬁcation. We speciﬁcally compared these
changes in patients receiving HIST, low-intensity
statin therapy (LIST), and no-statin therapy.
METHODS
STUDY POPULATION. The present analysis included
patients participating in 8 clinical trials assessing the
impact of medical therapies on serial changes in coro-
nary atheroma burden using IVUS. Included in this
analysis were trials assessing intensive lipid lowering
with statins (REVERSAL [Reversal of Atheroscle-
rosis With Aggressive Lipid Lowering] and SATURN
[The Study of Coronary Atheroma by Intravascular Ul-
trasound: Effect of Rosuvastatin Versus Atorvastatin])
me(2,15), antihypertensive therapies (AQUARIUS [Alis-
kiren Quantitative Atherosclerosis Regression Intra-
vascular Ultrasound Study] and NORMALIZE [Norvasc
for Regression of Manifest Atherosclerotic Lesions by
Intravascular Sonographic Evaluation]) (16,17), the
antiatherosclerotic efﬁcacy of acyl-coenzyme A:cho-
lesteryl ester transfer protein inhibition (ACTIVATE
[ACAT Intravascular Atherosclerosis Treatment Evalu-
ation]) (18), cholesteryl ester transfer protein inhibition
(ILLUSTRATE [Investigation of Lipid Level Manage-
ment Using Coronary Ultrasound to Assess Reduction
of Atherosclerosis by CETP Inhibition and HDL
Elevation]) (19), endocannibanoid receptor antago-
nism (STRADIVARIUS [Strategy to Reduce Athero-
sclerosis Development Involving Administration of
Rimonabont—The Intravascular Ultrasound Study])
(20), and the peroxisome proliferator–activated re-
ceptor-gamma agonism (PERISCOPE [Pioglitazone
Effect on Regression of Intravascular Sonographic
Coronary Obstruction Prospective Evaluation]) (21).
The ASTERIOD (A Study to Evaluate the Effect of
Rouvastatin on Intravascular-Ultrasound Derived
Indices of Coronary Atheroma Burden) study was not
included in this analysis because smoking status and
C-reactive protein (CRP) levels were not collected (1).
From each of these trials, patients receiving HIST
(n ¼ 1,545), LIST (n ¼ 1,726), or no-statin therapy
(n ¼ 224) were included in the present analysis. In the
present analysis, HIST was deﬁned as atorvastatin 80
mg or rosuvastatin 40 mg, whereas LIST was deﬁned
as atorvastatin dosing <40 mg, rosuvastatin <20 mg,
simvastatin <40 mg, pravastatin <80 mg, lovastatin
<20 mg, and ﬂuvastatin dosing <40 mg. Hence, the
present analysis comprises a patient-level analysis of 8
randomized trials in which patients were stratiﬁed on
the basis of statin treatment (or no-statin treatment).
ACQUISITION AND ANALYSIS OF SERIAL IVUS IMAGES.
The acquisition and serial analysis of IVUS images
in each of these trials has been previously described in
detail (1,2,15,17–22). Brieﬂy, target vessels for imaging
were selected if they contained no luminal stenosis
>50% angiographic severity within a segment of at
least 30mm length. Imaging was performedwithin the
same coronary artery at baseline and at study
completion, which ranged from 18 to 24 months. Im-
aging in all trials was screened by the Atherosclerosis
Imaging Core Laboratory of the Cleveland Clinic
Coordinating Center for Clinical Research. Patients
meeting pre-speciﬁed requirements for image quality
were eligible for randomization. An anatomically
matched segment was deﬁned at the 2 time points on
the basis of proximal and distal side branches (ﬁdu-
ciary points). Cross-sectional images spaced precisely
1 mm apart were selected for measurement. Leading
TABLE 1 Baseline Demographics, Clinical Characteristics,
and Medications
High-Intensity
Statin
(n ¼ 1,545)
Low-Intensity
Statin
(n ¼ 1,726)
No-Statin
(n ¼ 224)
Age, yrs 57.1  8.8 58.4  9.3 59.5  9.9
Female 413 (26.7) 514 (29.8) 69 (30.8)
Body mass index, kg/m2 29.7  5.6 31.2  5.9 32.7  6.8
Diabetes 327 (21.2) 549 (31.8) 101 (45.1)
Hypertension 1,101 (71.3) 1,357 (78.6) 182 (81.3)
Current smoker 468 (30.3) 361 (20.9) 40 (18.0)
History of MI 432 (28.0) 479 (27.8) 52 (23.2)
History of PCI 539 (34.9) 734 (42.5) 64 (28.6)
History of CABG 19 (1.2) 49 (2.8) 4 (1.8)
History of PAD 58 (3.8) 86 (5.0) 20 (8.9)
History of CVA 38 (2.5) 60 (3.5) 9 (4.0)
Prior statin use 1,045 (67.6) 1,473 (85.3) 15 (6.7)
Baseline aspirin 1,451 (93.9) 1,594 (92.4) 185 (82.6)
Baseline beta blockers 1,170 (75.7) 1,252 (72.5) 145 (64.7)
Baseline ACE inhibitor/ARB 942 (61.0) 1,121 (64.9) 128 (57.1)
Baseline nitrates 324 (21.0) 454 (26.3) 78 (34.8)
Values are mean  SD or n (%). Prior statin use was deﬁned as statin use on any
occasion prior to study enrolment.
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin receptor blocker;
CABG ¼ coronary artery bypass graft; CVA ¼ cerebrovascular accident;
MI ¼ myocardial infarction; PAD ¼ peripheral arterial disease; PCI ¼ percutaneous
coronary intervention.
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1275edges of the lumen and external elastic membrane
were traced by manual planimetry. Plaque area was
deﬁned as the area occupied between these leading
edges. The accuracy and reproducibility of thismethod
have been reported previously (23). The percent
atheroma volume (PAV) was determined by calcu-
lating the proportion of the entire vessel wall occupied
by atherosclerotic plaque, throughout the segment of
interest as follows:
PAV ¼
PðEEMarea  LumenareaÞP
EEMarea
 100
The total atheroma volume (TAV) was calculated
by summating the plaque areas in all measured im-
ages. To account for heterogeneity of segment length
in individual subjects, the TAV was normalized by
multiplying the mean atheroma area in each pullback
by the median segment length for the entire study
cohort as follows:
TAVNormalized ¼
PðEEMarea  LumenareaÞ
Number of Images in Pullback
Median number of images in cohort
Calcium was identiﬁed by an echogenic signal
brighter than the adventitia with corresponding
acoustic shadowing. A calcium grade was assigned for
each analyzed image, reﬂecting the degree of acoustic
shadowing (0 ¼ no calcium; 1 ¼ calcium with acoustic
shadowing <90; 2 ¼ calcium with shadowing $90
but <180; 3 ¼ calcium with shadowing $180 but
<270; 4 ¼ calcium $270) (13,24). For images con-
taining multiple calcium deposits, the grade repre-
sented the summation of all angles of acoustic
shadowing. For each pullback, a calcium index (CaI)
was thus calculated as follows (25):
CaI ¼ Total no: of analyzed frames with any Calcium
Total no: of analyzed frames
Maximal arc of Calcium
4
Change in CaI was deﬁned as follow-up CaI minus
baseline CaI.
STATISTICAL ANALYSIS. Continuous variables were
reported as mean  SD if normally distributed and as
median (interquartile range) if non-normally distrib-
uted. Demographics, baseline clinical characteristics,
baseline medications, laboratory biochemical data,
and baseline IVUS parameters were compared. Two-
sample Student t tests were used for normally
distributed continuous variables, Wilcoxon rank
sum tests for non-normally distributed continuous
variables, and chi-square tests (or exact tests) for
categorical variables.Because of differences in various baseline charac-
teristics across the treatment groups, a propensity
score weighting method was applied. The multiple
treatment propensity scores and corresponding in-
verse probability of treatment weight (the reciprocal
of the propensity scores) were estimated by general-
ized boosted models using an iterative estimation
procedure (26), using all the related baseline charac-
teristics and medications as covariates. The balance
of the pre-treatment covariates was assessed, and
signiﬁcant improvement in baseline balance was
achieved following weighting.
All subsequent analyses were weighted by inverse
probability of treatment weight, except the analysis
of baseline CaI. Serial changes in IVUS measurements
were analyzed by analysis of covariance, adjusting for
their baseline counterparts, and are reported as least
squares mean  SE, and the causal effects of each
therapy were examined using inverse probability of
treatment weight weighted generalized linear
regression models in the context of survey design
controlling for baseline IVUS values. Such survey-
weighted generalized linear models have robust
design-based standard errors. Because the CaI (both
baseline and change) had many zero values, a rank-
transformation was performed, and the same strat-
egy of survey-design generalized linear models was
created using the rank-transformed CaI changes as
TABLE 2 Laboratory Findings*
High-Intensity Statin
(n ¼ 1,545)
Low-Intensity Statin
(n ¼ 1,726)
No-Statin
(n ¼ 224)
Baseline
LDL-C 119.5  33.8 96.3  33.9 110.0  36.2
HDL-C 43.9  11.0 44.0  12.0 41.7  14.2
Non–HDL-C 149.8  39.5 126.6  40.1 141.9  39.2
Triglycerides 137.5 (97–190) 135 (97–193) 157.7 (106.2–228)
apoB 110.3  30.8 91.3  35.7 96.2  28.3
apoA-1 126.0  24.5 127.9  28.0 133.3  33.6
apoB:apoA-1 0.83  0.24 0.64  0.22 0.78  0.45
CRP 1.8 (0.9–4.3) 2.4 (1.1–5.4) 3.1 (1.4–6.4)
Follow-up
LDL-C 70.8  25.5 89.1  25.0 107.2  30.9
HDL-C 48.0  12.2 50.7  17.1 43.5  14.9
Non–HDL-C 96.6  29.0 117.2  30.8 138.8  34.3
Triglycerides 117.7 (90.4–158.5) 129.6 (94.0–177.4) 150.7 (105.2–216.3)
apoB 76.8  21.5 82.9  27.6 93.5  27.2
apoA-1 140.5  24.6 138.9  29.9 135.3  28.1
apoB:apoA-1 0.55  0.17 0.57  0.20 0.72  0.25
CRP 1.1 (0.6–2.8) 2.0 (0.9–4.4) 2.6 (1.1–5.1)
Change from baseline
LDL-C
% change -36.2  29.5 -2.2  28.5 2.8  24.6
p value† <0.001 0.002 0.10
HDL-C
% change 11.0  20.1 16.4  27.9 10.3  73.5
p value† <0.001 <0.001 0.04
Non–HDL-C
% change -31.9  25.5 -3.7  23.5 -0.6  18.8
p value† <0.001 <0.001 0.66
Triglycerides
Median of % change -12.8 -5.2 -3.6
p value‡ <0.001 <0.001 0.72
apoB
% change -27.6  21.7 -4.8  28.7 -0.02  26.3
p value† <0.001 <0.001 0.99
apoA-1
% change 13.2  18.6 11.8  37.0 7.4  45.8
p value† <0.001 <0.001 0.052
apoB:apoA-1
% change -32.3  19.6 -8.7  27.5 -2.0  24.0
p value† <0.001 <0.001 0.30
CRP
Median of % change -33.3 -17.6 -19.6
p value‡ <0.001 0.001 0.52
Values are mean  SD or median (95% conﬁdence interval). *Unless otherwise noted, laboratory values obtained
during treatment are the time-weighted averages of all post-baseline values. †P value for test of % change ¼ 0.
‡p value for signed rank test. All lipoprotein measurements are in mg/dl. CRP measurements are mg/l.
apoA-1 ¼ apolipoprotein A-1; apoB ¼ apolipoprotein B; CRP ¼ C-reactive protein; HDL-C ¼ high-density
lipoprotein cholesterol; LDL-C ¼ low-density lipoprotein cholesterol.
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1276the outcome. Because calcium is a component of
plaque, atheroma volume (PAV or TAV) was adjusted
within the model for CaI. Clinical trial and baseline
CaI were controlled for in the CaI model as well.
Average treatment effects on IVUS and on CaI were
compared in a pairwise fashion among the statin
therapy groups. Given that each trial’s duration variedbetween 18 and 24 months, changes in PAV, TAV, and
CaI were also interpolated at 1 year and thus reported
as annualized changes. Because of the intrinsic rela-
tionships between plaque progression and calciﬁca-
tion, changes in coronary atheroma volume and CaIs
were also compared according to plaque progression/
nonprogression. A 2-sided probability value of 0.05
was considered statistically signiﬁcant. Analyses
were performed using SAS software version 9.2 (SAS
Institute, Cary, North Carolina) and the twang package
and survey package in (open-source) R software.
RESULTS
CLINICAL CHARACTERISTICS OF THE STUDY
POPULATION. Table 1 describes baseline demo-
graphics, clinical characteristics, and medication use
in each of the treatment groups. Signiﬁcant trends for
between-group differences were noted across certain
baseline variables. The no-statin group was of older
age, more likely female, had a higher body mass
index, and had a higher incidence of diabetes mellitus,
hypertension, peripheral arterial disease, and nitrate
use compared with the HIST and LIST groups.
BASELINE AND CHANGES IN LABORATORY MEASURES.
Table 2 describes baseline, follow-up, and changes
in laboratory biochemical measures within each
treatment group. Signiﬁcant trends for between-group
differences were noted across various baseline labo-
ratory variables. Patients receiving HIST had the
highest baseline LDL-C levels (119.5  34 mg/dl) but
the lowest CRP levels (1.8 mg/l). The no-statin group
had the lowest baseline high-density lipoprotein
cholesterol levels (41.7  14 mg/dl) but the highest
triglyceride (158 [106 to 228] mg/dl) and CRP levels (3.1
[1.4 to 6.4] mg/l). At follow-up, patients receiving HIST
had the lowest levels of LDL-C, non–high-density
lipoprotein cholesterol, triglycerides, and CRP com-
pared with the LIST and no-statin groups (LDL-C, 70.8
 26 mg/dl vs. 89.1  25 mg/dl vs. 107.2  31 mg/dl,
respectively; non–high-density lipoprotein choles-
terol, 96.6 29 mg/dl vs. 117.2 31 mg/dl vs. 138.8 34
mg/dl, respectively; triglycerides, 118 [90 to 159] mg/dl
vs. 130 [94 to 177] mg/dl vs. 151 [105 to 216] mg/dl,
respectively; CRP, 1.8 [0.6 to 2.8] mg/l vs. 2.0 [0.9 to
4.4] mg/l vs. 2.6 [1.1 to 5.1] mg/l, respectively).
BASELINE AND CHANGES IN CORONARY ATHEROMA
VOLUME ACCORDING TO THERAPY. Table 3 describes
baseline and changes in PAV and TAV of each treat-
ment group, and pairwise comparisons for changes in
atheroma volume following propensity-weighting.
Baseline PAV was 36.9  8.9%, 38.0  9.0%, and
37.2  9.0% in the HIST, LIST, and no-statin groups,
respectively. The HIST group had signiﬁcantly lower
TABLE 3 Baseline and Change in Coronary Atheroma Volume According to Treatment Allocation
IVUS Parameter
Therapies
High-Intensity
Statin
(n ¼ 1,545)
Low-Intensity
Statin
(n ¼ 1,726)
No-Statin
(n ¼ 224)
Predicted Mean Difference (95% CI), p Value
High vs. Low No vs. Low High vs. No
Percent atheroma volume, %
Baseline 36.9  8.9 38.0  9.0 37.2  9.0 -1.1 (-1.8 to -0.3), p ¼ 0.002 -0.8 (-2.3 to 0.7), p ¼ 0.40 -0.3 (-1.8 to 1.2), p ¼ 0.91
Change from baseline -0.6  0.1 0.8  0.1 1.0  0.1 -1.4 (-1.7 to -1.1), p < 0.001 0.2 (-0.3 to 0.7), p ¼ 0.35 -1.6 (-2.1 to -1.1), p < 0.001
Annualized changes -0.3  0.1 0.5  0.1 0.6  0.1 -0.8 (-0.9 to -0.6), p < 0.001 0.1 (-0.1 to 0.4), p ¼ 0.32 -0.9 (-1.2 to -0.6), p < 0.001
p value for test of change ¼ 0* <0.001 <0.001 <0.001
Total atheroma volume, mm3
Baseline 183.9  81 188.2  84 195.3  87 -4.4 (-11 to 2.4), p ¼ 0.29 7.0 (-6.7 to 21), p ¼ 0.46 -11.4 (-25.3 to 2.5), p ¼ 0.13
Change from baseline -6.6  0.6 -2.1  0.6 3.0  0.7 -4.4 (-6.1 to -2.8), p < 0.001 5.1 (1.5 to 8.8), p ¼ 0.006 -9.6 (-13 to -5.9), p < 0.001
Annualized changes -3.2  0.4 -1.1  0.3 1.8  0.4 -2.1 (-3.1 to -1.2), p < 0.001 2.9 (0.9 to 5.0), p ¼ 0.005 -4.9 (-6.9 to -2.9), p < 0.001
p value for test of change ¼ 0* <0.001 <0.001 <0.001
Baselinevalues aremean SD, changevalues are least squaresmean SEcontrolling for thebaseline counterpart. Pairwise comparisons for baseline IVUSwere conductedusing thegeneral linearmodel. Pairwise
comparisons for changes in IVUS parameters from baseline were conducted using survey-design inverse probability of treatment weight weighted generalized linear models. *From Wilcoxon signed rank test.
CI ¼ conﬁdence interval; IVUS ¼ intravascular ultrasound.
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1277PAV at baseline compared with the LIST group
(p ¼ 0.002). At follow-up, the HIST group demon-
strated signiﬁcant PAV regression from baseline
(0.6  0.1%; p < 0.001), whereas both the LIST and
no-statin groups each demonstrated signiﬁcant PAV
progression (þ0.8  0.1% and þ1.0  0.1%; p < 0.001
from baseline, respectively). These changes in PAV
differed signiﬁcantly for pairwise comparisons be-
tween the HIST versus LIST (p < 0.001) and the HIST
versus no-statin groups (p < 0.001) (Figure 1A).
Baseline TAV was similar across all treat-
ment groups, with no signiﬁcant between-group dif-
ferences. At follow-up, both the HIST and LIST groups
demonstrated signiﬁcant TAV regression from base-
line (6.6  0.6 mm3 and 2.1  0.6 mm3; p < 0.001FIGURE 1 Statins and Coronary Plaque Calciﬁcation: Changes in Coro
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1278for baseline CaI. However, the TAV-adjusted model
yielded signiﬁcantly greater baseline CaI for the
LIST versus no-statin (p ¼ 0.002) and HIST versus
no-statin (p ¼ 0.001) pairwise comparisons.
All treatment groups demonstrated signiﬁcant pro-
gression of coronary calcium from baseline, measured
as a change in CaI (HIST, þ0.044 [0.0 to 0.12];
LIST, þ0.038 [0.0 to 0.11]; no-statin, þ0.02 [0.0 to
0.10]; p < 0.001 for all treatment groups). In a PAV-
adjusted model, pairwise comparisons demonstrated
that the change in CaI was signiﬁcantly greater in the
LIST versus no-statin groups (p ¼ 0.03) and the HIST
versus no-statin groups (p ¼ 0.007), but not for the
HIST versus LIST comparison (p¼0.18) (Figure 1A). In a
TAV-adjusted model, similar results were found, with
pairwise comparisons demonstrating the change in CaI
to be signiﬁcantly greater in the LIST versus no-statin
groups (p ¼ 0.01) and the HIST versus no-statin
groups (p ¼ 0.004), but not for the HIST versus LIST
comparison (p ¼ 0.35) (Figure 1B).
CHANGES IN CORONARY ATHEROMA VOLUME AND CaI
ACCORDING TO PLAQUE PROGRESSION/REGRESSION.
Table 5 describes changes in plaque volume and CaI
stratiﬁed according to whether patients exhibited
plaque progression (deﬁned as change in PAV or TAV
>0) or nonprogression/regression (change in PAV or
TAV #0). Those with plaque progression demon-
strated an overall þ2.7  0.05% and þ7.5  0.5 mm3
change in PAV and TAV, respectively, whereas
nonprogressors/regressors demonstrated an overall
2.2  0.06% and 13.1  0.5 mm3 change in PAV
and TAV, respectively. Changes in CaI were signiﬁ-
cantly greater in those with plaque progression
compared with those with nonprogression/regres-
sion irrespective of whether adjusted for by changes
in PAV (0.045 [0.00 to 0.12] vs. 0.034 [0.00 to 0.11];
p ¼ 0.002) or changes in TAV (0.045 [0.00 to 0.12]
vs. 0.034 [0.00 to 0.11]; p < 0.001).
RELATIONSHIPS BETWEEN CHANGES IN CaI AND
ON-TREATMENT LIPOPROTEINS AND CRP. Table 6
describes correlations between changes in CaI and
average on-treatment lipoprotein and CRP levels
among patients receiving HIST and no-statin therapy.
No signiﬁcant correlations were found between HIST-
mediated changes in lipoprotein or CRP levels and
changes in CaI. Similarly, no signiﬁcant associations
were found between changes in lipoprotein and CRP
levels and changes in CaI in those patients receiving
no-statin therapy.
DISCUSSION
In this post-hoc propensity-weighted analysis of pa-
tients with coronary artery disease undergoing serial
TABLE 5 Changes in Coronary Atheroma Volume and Calcium Indices According to
Plaque Progression/Regression
Parameter
Change Parameter Comparison
Plaque
Progressors
Plaque
Nonprogressors
or Regressors
LS Mean
Difference
(95% CI) p Value
Change in PAV, % 2.7  0.05 -2.2  0.06 4.9 (4.7–5.0) <0.001
Annualized change 1.6  0.03 -1.2  0.03 2.8 (2.7–2.9) <0.001
Change in TAV, mm3 7.5  0.50 -13.1  0.5 20.6 (19.3–21.9) <0.001
Annualized change 4.5  0.30 -7.2  0.3 11.7 (11.0–12.5) <0.001
Median (IQR) for
Progressors
Median (IQR) for
Nonprogressors or
Regressors t Value* p Value*
Change in CaI
(PAV adjusted)
0.045 (0.00–0.012) 0.034 (0.00–0.11) 3.1 <0.002
Annualized change 0.025 (0.00–0.070) 0.018 (0.00–0.054) 3.2 0.001
Change in CaI
(TAV adjusted)
0.045 (0.00–0.12) 0.034 (0.00–0.11) 4.1 <0.001
Annualized change 0.025 (0.00–0.070) 0.018 (0.00–0.054) 4.2 <0.001
Progressors deﬁned as change in PAV or TAV >0; nonprogressors deﬁned as change in PAV or TAV #0. Changes
in plaque burden are reported as reported as mean  SD. Change in PAV and TAV are obtained from linear mixed
models controlling for the baseline counterpart. *Values are from the linear mixed models for rank transformed
change in calcium index, controlling for baseline calcium index ranks, baseline plaque burden, change in plaque
burden, and clinical trial. The t value has 3,483 degrees of freedom.
CaI ¼ calcium index; IQR ¼ interquartile range; LS ¼ least squares; other abbreviations as in Tables 3 and 4.
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1279coronary IVUS, we demonstrate the signiﬁcant pro-
calciﬁc effects of both high- and low-intensity statins,
and the calciﬁc nature of coronary atheroma pro-
gression in statin-naive patients during follow-up.
The novel ﬁnding of this analysis was the dominant
inﬂuence of statins on changes in plaque calciﬁcation,
irrespective of net plaque progression or regression.
The greatest increases in calcium were evident
in patients receiving HIST to coincide with signiﬁ-
cant plaque regression, and statin-naive patients
demonstrated the smallest increase in plaque calciﬁ-
cation over time, despite profound atheroma pro-
gression. Despite both the LIST and no-statin groups
each demonstrating comparable degrees of serial
plaque progression, the increases in CaI within the
LIST group were double that of the no-statin group.
These ﬁndings point to possible procalciﬁc effects of
statins, which are consistent with possible plaque-
stabilizing effects of statins beyond simply their
effects on atheroma volume.
At ﬁrst glance, the signiﬁcant increase in coronary
calciﬁcation following HIST seems paradoxical to the
demonstrated net plaque regression in these patients.
Prior investigations testing the serial effects of statins
on coronary calcium have largely been undertaken
via calcium scoring using CT, and ﬁndings across
those studies were inconsistent (6–11). Common to
most of those studies was the comparatively shorter
follow-up period and smaller sample sizes. Achieved
LDL-C levels were often >100 mg/dl following the
use of mild statin regimens, not reﬂective of current
practice guidelines for patients with atherosclerotic
cardiovascular disease (4). Moreover, the lack of
plaque volume measurement in those studies limited
their ability to truly ascertain statin-mediated effects
on the vessel wall. It is important to note, however,
that calcium-scoring via CT also has a much lower
resolution compared with IVUS, with CT capable
of detecting only relatively large calcium depositsTABLE 6 Relationships of Change in CaI With Average Follow-Up Lip
High-Intensity Statins or No-Statins*
LDL-C apoB HDL-C
R p Value R p Value R p Value R
High-intensity statin therapy
DCaI† -0.02 0.41 -0.003 0.90 0.02 0.39 0.0
DCaI‡ -0.003 0.92 0.005 0.85 0.02 0.44 0.0
No-statin therapy
DCaI† 0.04 0.54 0.10 0.21 0.10 0.12 0.1
DCaI‡ 0.03 0.69 0.09 0.24 0.10 0.15 0.1
Baseline and change in CaI were rank transformed. Average follow-up CRP and triglycerid
follow-up lipid parameters and the residuals of change in calcium index using rank analy
burden, and clinical trial. †Plaque variable that was adjusted in the model was PAV. ‡Pl
Abbreviations as in Tables 2 and 4.(1.03 to 1.37 mm2) (27). Conversely, the higher reso-
lution of IVUS in the present analysis was sensitive
enough to elucidate subtle, yet signiﬁcant, changes in
atheroma calciﬁcation, in addition to changes in pla-
que volume. Hence, it remains unclear how the ﬁnd-
ings of the present analysis relate to the measured
effects of statins on CT scanning. Nevertheless, the
current analysis is the ﬁrst to simultaneously describe,
in a large number of patients, the evolution of both
coronary calcium and atheroma volume following
mild and potent statin regimens, as well as in patients
with coronary artery disease remaining statin-naive.
Findings of the present analysis are supported
by several prior clinical and pre-clinical observations.
In individuals with diabetes, statin use independentlyoprotein and CRP Levels in Patients Receiving
apoA-1 apoB/apoA-1 CRP Triglycerides
p Value R p Value R p Value R p Value
4 0.16 -0.04 0.21 0.02 0.43 0.01 0.59
4 0.19 -0.02 0.39 0.03 0.29 0.01 0.62
1 0.19 0.03 0.68 0.04 0.62 0.005 0.94
3 0.11 0.02 0.80 0.02 0.73 0.02 0.81
es values were log transformed. *Pearson correlation coefﬁcient (R) between average
sis of variance, controlling for baseline CaI, baseline plaque burden, change in plaque
aque variable that was adjusted in the model was TAV.
CENTRAL ILLUSTRATION Plaque Calciﬁcation in the Setting of No-Statin Therapy or High-Intensity Statin Therapy
Natural plaque progression likely involves lipid-pool expansion coupled with microcalciﬁcations within lipid pools. Following long-term high-intensity
statin therapy, plaque regression manifests as delipidation and probable vascular smooth muscle cell calciﬁcation, promoting plaque stability.
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1280associated with progressive coronary atheroma calci-
ﬁcation (28,29), with similar observations on CT noted
in nondiabetic individuals receiving statins from
MESA (Multi-Ethic Study of Atherosclerosis) (30).
A trend toward increasing atheroma calciﬁcation
following statins was also reported by several other
investigators (11,31–33). Although lacking a placebo-
controlled arm, serial coronary plaque compositional
analyses via interrogation of the ultrasonic radio-
frequency IVUS backscatter signal were consistent in
demonstrating progressive coronary calciﬁcation
following aggressive statin therapy (34,35). Serial
ultrasonic carotid evaluation also revealed intensive
statin therapy to cause greater increases in plaque
echogenicity compared with a less intensive statin
regimen (36,37). Importantly, changes in plaque
echogenicity correlated inversely with changes in
levels of serum inhibitors of vascular calciﬁcation
(osteopontin and osteoprotegerin), which were inde-
pendent of alterations of lipid proﬁle. Our analysisalso failed to demonstrate associations between
changes in CaI with on-treatment lipoprotein or
CRP levels during statin treatment, suggesting that
the procalciﬁc effects of statins are possibly mediated
by pleiotropic mechanisms unrelated to lipoprotein
metabolism.
Pre-clinical studies testing the modulatory effects
of statins on vascular smooth muscle cells have also
yielded conﬂicting results; however, this may depend
on the nature of calciﬁcation-induction method
performed in vitro. Following an inﬂammation-
induced calciﬁcation model, statins inhibited vas-
cular smooth muscle cells calciﬁcation, consistent
with their known anti-inﬂammatory pleiotropic ef-
fects (38). However, using a noninﬂammatory organic
phosphate model of in vitro calciﬁcation, statins dose-
dependently stimulated vascular smooth muscle cells
apoptosis and subsequent calciﬁcation (12). Despite
these paradoxical ﬁndings, such mechanistic obser-
vations are consistent with pathological observations
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Serial analysis of
coronary atheroma in vivo demonstrates that despite the asso-
ciation with plaque regression, statins possess procalciﬁc effects
related to the intensity of therapy.
TRANSLATIONAL OUTLOOK: Further research should be
directed toward understanding the mechanisms responsible for
plaque calciﬁcation that occurs during statin therapy and iden-
tifying those that concurrently stabilize coronary atheroma.
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1281pointing to a central role of vascular smooth muscle
cells and macrophage apoptosis driving plaque calci-
ﬁcation in humans (39,40). The ﬁnding of progressive
atheroma calciﬁcation in the no-statin group, who
demonstrated marked atheroma progression, is also
consistent with pathological observations of micro-
calciﬁcations within plaque lipid pools (41), which can
coalesce into speckles and fragments during atheroma
progression (Central Illustration) (40).
Aside from lipid regression within plaques
following long-term potent statin therapies (35),
statin-mediated atheroma calciﬁcation may improve
plaque stability. Microcalciﬁcations are commonly
found within an overlying ﬁbrous cap, and were
once thought to enhance the risk of plaque rup-
ture (42). However, more recent research suggests
that a very low proportion of plaques containing
microcalciﬁcation actually rupture (43), and that if
statins rendered plaque microcalciﬁcations more
conﬂuent and dense, then vessel wall stresses might
fall considerably, contributing to plaque stability
(44). The current analysis provides supportive evi-
dence for the possible plaque-stabilizing effects of
statins via inducing microcalciﬁcation.
STUDY LIMITATIONS. Despite a rigorous statistical
approach to account for the differences of baseline
characteristics and trial effect, we cannot exclude the
possibility of unmeasured confounding variables
biasing our results. However, inclusion/exclusion
criteria for all these trials were relatively uniform, and
all analysis was performed within a single core labo-
ratory using standardized analytical techniques. The
exact reasons for 224 patients with demonstrable cor-
onary disease not to be prescribed statins during an 18-
to 24-month trial period are unclear. However, these
patients pose as an extremely unique population
exhibiting the true phenotype of untreated, progres-
sive coronary atherosclerosis, unlikely ever to be
formally prospectively investigated in a plaque imag-
ing study again. Depth analysis of calcium is not a
standard component of our core laboratory’s IVUS
imaging protocol, and the degree of calcium was
ultimately coded semiquantitatively. Therefore, we
cannot comment on the precise nature or phenotype
of statin versus non–statin-induced serial coronarycalciﬁcation. However, unique to the present analysis
is the accurate and concomitant assessment of
serial changes in coronary atheroma volume across the
entire length (median length of 50 mm) of the imaged
vessel. Furthermore, we sampled a single epicardial
coronary artery as a broad representation of the coro-
nary vasculature. Therefore, ﬁndings of the present
analysis do not apply to patients with pre-existing
extensive coronary calciﬁcation, nor are such ﬁnd-
ings directly applicable to angiographically severe or
hemodynamically signiﬁcant lesions. Serum osteo-
pontin and osteoprotegerin were not measured,
therefore we can only speculate on mechanisms pro-
moting statin-induced plaque calciﬁcation. Lastly,
none of these serial IVUS trials were powered for de-
tecting differences in clinical events, and therefore no
speciﬁc association to clinical event rates can be drawn
from the present analysis. Nevertheless the plaque-
stabilizing effects and mortality beneﬁt of statins in
patients with atherosclerosis are well described (3).
CONCLUSIONS
The present analysis provides unique insight into
the procalciﬁc effects of prolonged statin therapy
on coronary atheroma in vivo, potentially under-
scoring the plaque-stabilizing effects of statins.
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